US · Healthcare · Medical Devices
EPS came in at 0.07 against a street estimate of 0.04 — a beat of 75.0%.
Analysts rate Neogen Corporation a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $14.00.
CONFIDENT Neogen reported strong first-quarter core growth, raised FY27 revenue and EBITDA guidance, and advanced Petrifilm transition preparations while continuing targeted investments. Q1 FY27 Growth was reported in every region, led by double-digit Asia Pacific growth; currency benefits moderated sequentially. Analysts pressed on margin timing, market-share gains, segment growth, Petrifilm transition risks, and innovation partnerships. Management emphasized disciplined execution, targeted investment, and staged transition controls. 2026-10-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.31% |
| Neuberger Berman Group LLC | 7.59% |
| Vanguard Portfolio Management, LLC | 5.97% |
| Dimensional Fund Advisors, Inc. | 4.50% |
| Vanguard Capital Management, LLC | 4.42% |
| SG Americas Securities, LLC | 4.28% |
| T. Rowe Price Investment Management,Inc. | 4.28% |
| ING Groep NV | 4.17% |
| Document | Date |
|---|---|
| Quarterly report · Q1 FY2027 HEADLINE NUMBERS • Revenue rose 6.5% to $222.8 million in the three months ended August 31, 2026, from $209.2 million a year earlier. • Gross profit | 2026-10-07 |
| Shareholder vote results · Q2 FY2027 OTHER NOTABLE POINTS • Neogen Corporation held its 2026 Annual Meeting of Shareholders on October 1, 2026. • 176,180,487 of the 218,106,005 outstand | 2026-10-07 |
| Results announced · Q2 FY2027 HEADLINE NUMBERS • First-quarter fiscal 2027 revenue was $222.8 million, up 6.5% from $209.2 million; Core Growth was 8.1%. • Net loss was $11.9 mil | 2026-10-06 |
| Proxy statement · Q1 FY2027 NEOGEN CORPORATION PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of three Class III directors for three-year t | 2026-08-21 |
| Board / officer change · Q1 FY2027 NEOGEN CORPORATION – 8-K FILING SUMMARY HEADLINE NUMBERS • Filing Date: August 7, 2026 (Event Date: August 3, 2026) • Company: Neogen Corporation (T | 2026-08-07 |
| Annual report FY2026 NEOGEN CORPORATION – 10-K SUMMARY FOR RETAIL INVESTORS Fiscal Year Ended May 31, 2026 --- HEADLINE NUMBERS • Market Value (as of Nov 30, 2025): $97 | 2026-07-30 |
| Results announced · Q1 FY2027 NEOGEN CORPORATION – FY2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • FY2026 Total Revenue: $870.4 million, down 2.7% year-over-year (prior year: | 2026-07-30 |
| Reg FD disclosure · Q4 FY2026 NEOGEN CORPORATION 8-K SUMMARY HEADLINE NUMBERS • No specific financial figures disclosed in this 8-K filing • Company is Neogen Corporation, traded | 2026-04-20 |
Readable in the app.
| Announcement | Date |
|---|---|
| Fiscal 2027 revenue and adjusted EBITDA guidance raised Neogen reported a solid first quarter of fiscal 2027. Revenue rose 6.5% to $222.8 million, or 8.1% on a core basis. Food Safety revenue increased 7.4% to $163.2 million, while Animal Safety | 2026-10-06 |
| FY2027 financial guidance provided for revenue and Adjusted EBITDA Neogen Corporation reported mixed fiscal year 2026 results. Full-year revenue was $870.4 million, down 2.7% year-over-year, though core growth (excluding divestitures) reached 1.9%. Fourth q | 2026-07-30 |
| Raised fiscal year 2026 revenue outlook; maintained Adjusted EBITDA guidance Neogen Corporation reported Q3 FY2026 revenue of $211.2 million, down 4.4% year-over-year, reflecting mixed business performance. Food Safety grew modestly at 2.6% core growth (4.0%), driven | 2026-04-09 |
| Q2 2026 results; raises FY 2026 revenue and Adjusted EBITDA guidance Neogen Corporation reported Q2 2026 results showing mixed near-term performance but positive strategic momentum. Revenue declined 2.8% year-over-year to $224.7 million, but core revenue (exc | 2026-01-08 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Neogen Corporation — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.